The company has said that all three of its CONNEX trials failed to meet expectations showing no significant impact on the ...

Boehringer Ingelheim’s trio of late-stage schizophrenia failures on Thursday came a day after the Department of Health and ...

HHS told the Second Circuit that Boehringer Ingelheim’s voluntary participation in Medicare negotiations “undermines” its ...

Boehringer Ingelheim announced a partnership with Synaffix to advance antibody-drug conjugates and exercised its fourth ...

Boehringer Ingelheim today announced top-line results from the Phase III CONNEX clinical program in cognitive impairment in adults with ...

After inking a series of partnerships late last year, Lonza’s antibody-drug conjugate (ADC) specialist Synaffix is kicking ...

Boehringer Ingelheim says it is on track to launch 25 new treatments in its human pharma division onto the market between now and 2030, fuelled by an R&D pipeline that it says is the best in its ...

Synaffix adds to the flurry of ADC dealmaking as it partners with Boehringer and Mitsubishi Tanabe with deals announced on ...

Boehringer Ingelheim BioXcellence™ and Sutro Biopharma Inc.today announced that they successfully applied Sutro’ ...

The heritage of Boehringer Ingelheim in developing medicines for respiratory diseases spans almost 100 years. Within the respiratory disease area, innovative treatments for chronic obstructive ...

Boehringer Ingelheim has licensed Synaffix B.V.’s ADC technology, significantly bolstering its ADC portfolio with the goal of ...

Equine Healthcare market Insights. BURLINGAME, CA, UNITED STATES, January 13, 2025 /EINPresswire / -- This report on the Equine Healthcare Market offers an ...